Vivozon Pharmaceutical continues its profit streak into the third quarter following the second quarter.
On the 14th, Vivozon Pharmaceutical announced that its consolidated sales for the third quarter of this year reached 18.4 billion KRW, a 33.8% increase compared to the same period last year. Operating profit for the same period was 1 billion KRW, and net profit was 200 million KRW, both turning positive.
Since restructuring its business, Vivozon Pharmaceutical has maintained continuous performance improvement. While strengthening investments in the pharmaceutical business, it has streamlined its optical and healthcare divisions.
The company cited growth in the prescription drug (ETC) sector, particularly cardiovascular, endocrine, and neurological products, as the reason behind the strong third-quarter performance. This year, Vivozon Pharmaceutical continued its growth centered on the cardiovascular chronic disease treatment JBICA tablets (hypertension) series and atorvastatin (hyperlipidemia). Additionally, it expanded its diabetes treatment lineup with products such as Daparozin tablets, Egliptin tablets, and Januvipo, enhancing its competitiveness.
Furthermore, the contract manufacturing organization (CMO) division contributed to improved performance by securing new contracts and enhancing profitability, leading to cumulative sales exceeding 15 billion KRW through the third quarter.
A Vivozon Pharmaceutical representative stated, “The improvement in profitability and growth-oriented business restructuring is directly reflected in our performance. We will strive to maintain the profit trend by enhancing production efficiency and product competitiveness.”
Meanwhile, on the 10th, Vivozon Pharmaceutical completed a stock consolidation to stabilize the stock price and enhance corporate value by maintaining an appropriate number of outstanding shares, and resumed stock trading.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
